Health Insurance for mRNA Refuseniks Should Cost Much Less Good Negotiating Chip to Wrangle Lower Premiums

With all-cause mortality among the mRNA-injected at least 20% higher than among the refuseniks, shouldn’t health insurance premiums paid by the refuseniks be 20% less than by the mRNA-injected?